|
A Phase I Trial of CC-5013 (lenalidomide) in Pediatric Patients with Recurrent or
|
Z01 BC 010585
|
$23,122
|
Warren, Katherine
|
CCR (NCI)
|
|
ABC Transporters in Human Disease and Multidrug Resistance
|
Z01 BC 005725
|
$579,181
|
Dean, Michael
|
CCR (NCI)
|
|
An Exploratory Study of Biologic and Pathophysiologic Efects of Radiation Therap
|
Z01 BC 010709
|
$92,488
|
Warren, Katherine
|
CCR (NCI)
|
|
Anatomic Pathology Residency Program
|
Z01 BC 010684
|
$1,300,000
|
Jaffe, Elaine
|
CCR (NCI)
|
|
Anticancer Drug Development for Childhood Cancers
|
Z01 SC 006880
|
$842,657
|
Balis, Frank
|
CCR (NCI)
|
|
Bcl-2 family proteins in the ER-mediated apoptosis
|
5K01CA098092-05
|
$124,308
|
ZONG, WEI-XING
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
BIOINFORMATICS: SYSTEMS BIOLOGY OF NEUROBLASTOMA
|
Z01 BC 011002
|
$122,346
|
Khan, Javed
|
CCR (NCI)
|
|
Brain Tumor Clinical and Clinical Research Program
|
Z01 BC 011098
|
$1,538,748
|
Fine, Howard
|
CCR (NCI)
|
|
Cancer Center Support (Core) Grant
|
5P30CA014051-37
|
$2,844,058
|
JACKS, TYLER
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
Cancer Center Support Grant
|
2P30CA013696-35
|
$3,785,244
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S1
|
$124,531
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S2
|
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S3
|
$49,998
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S4
|
$143,383
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S5
|
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA006516-44
|
$11,641,774
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
Cancer Center Support Grant
|
2P30CA008748-43
|
$13,879,527
|
VARMUS, HAROLD
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Cancer Center Support Grant
|
3P30CA008748-43S1
|
$144,142
|
VARMUS, HAROLD
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Cancer Center Support Grant
|
3P30CA091842-08S1
|
$87,870
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Cancer Center Support Grant
|
5P30CA091842-08
|
$4,017,997
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Cancer Center Support Grant P30 CA77598-06
|
3P30CA077598-10S3
|
$2,331,241
|
YEE, DOUGLAS
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
Chromosomal Proteins and Chromosomal Functions
|
Z01 BC 004496
|
$1,045,139
|
Bustin, Michael
|
CCR (NCI)
|
|
Clinical Development of Novel Drugs for Children with Refractory Cancers
|
Z01 SC 010354
|
$106,826
|
Widemann, Brigitte
|
CCR (NCI)
|
|
Clinical Pharmacogenetics
|
Z01 BC 010627
|
$436,963
|
Figg, William
|
CCR (NCI)
|
|
Clinical Pharmacology of Anticancer Drugs
|
Z01 BC 011080
|
$936,285
|
Balis, Frank
|
CCR (NCI)
|
|
Clinical trials of patients with AIDS-related malignancies
|
Z01 BC 010888
|
$679,281
|
Yarchoan, Robert
|
CCR (NCI)
|
|
Comparative Genomic Hybridization of Neuroblastoma
|
Z01 BC 010592
|
$40,782
|
Khan, Javed
|
CCR (NCI)
|
|
Comprehensive Cancer Center Core Support Grant
|
3P30CA013148-37S1
|
$72,878
|
PARTRIDGE, EDWARD
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Comprehensive Cancer Center Core Support Grant
|
3P30CA013148-37S2
|
$250,000
|
PARTRIDGE, EDWARD
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Comprehensive Cancer Center Core Support Grant
|
5P30CA013148-37
|
$5,700,309
|
PARTRIDGE, EDWARD
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Connecting PTEN and NF2 cancer predisposition syndromes
|
5R01CA107201-04
|
$254,494
|
GEORGESCU, MARIA-MAGDALENA
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Consequences of receptor cross talk on inflammation and algesia
|
Z01 BC 010708
|
$54,812
|
Oppenheim, Joost
|
CCR (NCI)
|
|
Determinants of Melanocyte Transformation and Melanoma Progression
|
Z01 BC 010565
|
$300,493
|
Hornyak, Thomas
|
CCR (NCI)
|
|
Determining the Fate of Transmembrane Proteins
|
Z01 BC 009392
|
$621,480
|
Weissman, Allan
|
CCR (NCI)
|
|
Development of Mouse Astrocytoma Model for Preclinical Testing
|
Z01 BC 010541
|
$87,292
|
Reilly, Karlyne
|
CCR (NCI)
|
|
Development of Recombinant Toxins to Treat Hematologic Malignancies
|
Z01 BC 010301
|
$558,572
|
Kreitman, Robert
|
CCR (NCI)
|
|
Development of Therapies for Neurofibromatosis Type 1 Related Tumors and other Ge
|
Z01 BC 010801
|
$427,304
|
Widemann, Brigitte
|
CCR (NCI)
|
|
DNA Repair in Human Cancer-Prone Genetic Diseases
|
Z01 BC 004517
|
$956,305
|
Kraemer, Kenneth
|
CCR (NCI)
|
|
Dynamic Regulation of Ras via the NF1 tumor Suppressor
|
5R01CA111754-04
|
$280,637
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Elucidating the role of the mTOR pathway in NF1-related tumorigenesis
|
5R01CA129814-02
|
$300,291
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Elucidation of NF2's tumor supressive function
|
5F32CA123752-03
|
$50,428
|
YI, CHUNLING
|
WISTAR INSTITUTE
|
|
Genetic Analysis of the Multidrug Resistance Phenotype in Tumor Cells
|
Z01 BC 005598
|
$758,163
|
Gottesman, Michael
|
CCR (NCI)
|
|
Histologic and Molecular Characterization of Solid Pediatric Tumors
|
Z01 SC 009431
|
$237,380
|
Tsokos, Maria
|
CCR (NCI)
|
|
Id2 in cell cycle regulation and cancer
|
5R01CA085628-09
|
$361,563
|
IAVARONE, ANTONIO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Identification and characterization of new mutants affecting Notch trafficking
|
Z01 BC 010913
|
$353,456
|
Fortini, Mark
|
CCR (NCI)
|
|
Identification of Genes for Predicting Prognosis in Pediatric Cancers
|
Z01 SC 010366
|
$67,970
|
Khan, Javed
|
CCR (NCI)
|
|
Identification of Modifier Gene of Tumors Associated with NF1 and Astrocytoma
|
Z01 BC 010539
|
$523,755
|
Reilly, Karlyne
|
CCR (NCI)
|
|
Identification of Novel Mutations In Pediatric Cancers
|
Z01 BC 010998
|
$339,850
|
Khan, Javed
|
CCR (NCI)
|
|
Identification of Single Nucleotide Polymorphisms in Cancer-Related Genes
|
Z01 BC 005652
|
$579,181
|
Dean, Michael
|
CCR (NCI)
|
|
IL-2/IL-15 Cytokine Receptor: Implications for Cancer Therapy and Vaccine Design
|
Z01 SC 004002
|
$1,493,105
|
Waldmann, Thomas
|
CCR (NCI)
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|